Tnf Pharmaceuticals Inc (TNFA) Stock Price, Quote & News

Company Profile

TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute and chronic inflammation. Th...

Industry: Biotechnology

Sector: Healthcare

Phone: 856 848 8698

Website: tnfpharma.com

Address:

1185 Avenue of the Americas, Suite 249, New York, United States

Jay111111111 Jun. 16 at 11:23 AM

$TNFA buy premarket

0 · Reply

Jay111111111 Jun. 16 at 3:51 AM

$TNFA buy in the premarket lets get the momentum, how are we doing tomorrow?

0 · Reply

Fishnet88 Jun. 14 at 3:29 PM

$TNFA Tick tack tick tack. The rocket are starting soon. 🚀🌕

0 · Reply

ka1954 Jun. 13 at 9:41 PM

$TNFA we had stocks that ran last week that deal with age related stuff, KLTO ran 2000%+ and i forget the other stock's name, but tnfa couldn't manage to even run complete 100%, it went like 98% or so and then went flat "TNF Pharmaceuticals is a clinical-stage pharmaceutical company focused on the development of drug products that represent a transformation in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety and sleep disorders. Our team has partnered with academic founders and key opinion leaders to identify synthetic therapeutics, including the first drug being designed to significantly increase human lifespan"

0 · Reply

SCTrader58 Jun. 13 at 6:03 PM

$TNFA too much volume on the failed run on Monday. Late buyers became the exit liquidity to run it lower. It should bottom the first half of next week but it will take several weeks to consolidate for another run. This is a mid to late July stock now IMO.

1 · Reply

SCTrader58 Jun. 13 at 5:56 PM

$TNFA .1360 is a key level. A close below takes the stock to .1110.

0 · Reply

lost200 Jun. 13 at 5:29 PM

$TNFA why did i touch this trash 🤣🤣

0 · Reply

Newtothisting Jun. 13 at 2:05 PM

$TNFA .10 soon

0 · Reply

nassermahashir Jun. 13 at 1:10 PM

$TNFA huge bounce will happen here They are coming again 🤑🤑..

2 · Reply

Bazzzigar Jun. 12 at 5:00 PM

$TNFA APDN WINT..

0 · Reply

TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists

Apr 22, 2025, 9:15 AM EDT - 2 months ago

TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development

Apr 16, 2025, 9:15 AM EDT - 2 months ago

TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025

Mar 17, 2025, 9:15 AM EDT - 3 months ago

TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia

Mar 5, 2025, 9:00 AM EST - 3 months ago

TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

Feb 25, 2025, 9:20 AM EST - 3 months ago

TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor

Jan 29, 2025, 9:15 AM EST - 4 months ago

TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment

Jan 15, 2025, 9:15 AM EST - 5 months ago

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Dec 19, 2024, 9:15 AM EST - 6 months ago

TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs

Dec 9, 2024, 9:00 AM EST - 6 months ago

TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference

Oct 2, 2024, 9:10 AM EDT - 9 months ago

TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market

Aug 21, 2024, 9:00 AM EDT - 10 months ago

TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline

Jul 24, 2024, 9:05 AM EDT - 11 months ago

TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol “TNFA” Effective Before Market Open Today

Jul 22, 2024, 9:00 AM EDT - 11 months ago

MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc.

Jun 17, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer

May 21, 2024, 9:00 AM EDT - 1 year ago

MyMD Pharmaceuticals Secures Strategic Investments

PMCB

May 21, 2024, 9:00 AM EDT - 1 year ago

PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease

PMCB

Mar 5, 2024, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Feb 13, 2024, 11:45 AM EST - 1 year ago

MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

Dec 29, 2023, 12:45 PM EST - 1 year ago

MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug

Dec 6, 2023, 9:15 AM EST - 1 year ago

MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis

Oct 19, 2023, 9:00 AM EDT - 1 year ago

MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain

Oct 4, 2023, 7:30 AM EDT - 1 year ago

MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023

Aug 14, 2023, 8:30 AM EDT - 2 years ago

FDA Accepts MyMD Pharmaceuticals' Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)

Aug 2, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results

Jul 31, 2023, 9:00 AM EDT - 2 years ago

MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty

Apr 12, 2023, 8:30 AM EDT - 2 years ago

MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Mar 20, 2023, 8:55 AM EDT - 2 years ago

MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis

Mar 8, 2023, 8:30 AM EST - 2 years ago

MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls

Mar 2, 2023, 8:30 AM EST - 2 years ago

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical

Feb 28, 2023, 8:30 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting

Feb 21, 2023, 8:45 AM EST - 2 years ago

MyMD Announces $15 Million Offering with Existing Investors

Dec 6, 2022, 9:40 AM EST - 2 years ago

ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Dec 6, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022

Nov 17, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress

Nov 14, 2022, 8:00 AM EST - 2 years ago

MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research

Aug 30, 2022, 8:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD™ Compound

Aug 3, 2022, 9:45 AM EDT - 3 years ago

Data Showing MyMD Pharmaceuticals' MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences

Jul 26, 2022, 7:30 AM EDT - 3 years ago

MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan

Jul 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions

Jun 21, 2022, 10:30 AM EDT - 3 years ago

MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Apr 12, 2022, 9:30 AM EDT - 3 years ago

MyMD Pharmaceuticals' Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Apr 5, 2022, 9:15 AM EDT - 3 years ago

MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Mar 24, 2022, 9:26 AM EDT - 3 years ago

MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

Feb 23, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

Feb 8, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

Jan 5, 2022, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

Dec 29, 2021, 9:15 AM EST - 3 years ago

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

ORMP

Jay111111111 Jun. 16 at 11:23 AM

$TNFA buy premarket

0 · Reply

Jay111111111 Jun. 16 at 3:51 AM

$TNFA buy in the premarket lets get the momentum, how are we doing tomorrow?

0 · Reply

Fishnet88 Jun. 14 at 3:29 PM

$TNFA Tick tack tick tack. The rocket are starting soon. 🚀🌕

0 · Reply

ka1954 Jun. 13 at 9:41 PM

0 · Reply

SCTrader58 Jun. 13 at 6:03 PM

1 · Reply

SCTrader58 Jun. 13 at 5:56 PM

$TNFA .1360 is a key level. A close below takes the stock to .1110.

0 · Reply

lost200 Jun. 13 at 5:29 PM

$TNFA why did i touch this trash 🤣🤣

0 · Reply

Newtothisting Jun. 13 at 2:05 PM

$TNFA .10 soon

0 · Reply

nassermahashir Jun. 13 at 1:10 PM

$TNFA huge bounce will happen here They are coming again 🤑🤑..

2 · Reply

Bazzzigar Jun. 12 at 5:00 PM

$TNFA APDN WINT..

0 · Reply

Jay111111111 Jun. 12 at 3:32 PM

$TNFA Market buy 1 share watch us hit the moon went from .14 to .1620 . Check my earlier posts

0 · Reply

Jay111111111 Jun. 12 at 3:10 PM

$TNFA To all soft hands , I’ll market buy all yall shares below .45 cents

0 · Reply

Jay111111111 Jun. 12 at 2:43 PM

$TNFA market buy 1 share every 1 minute and watch this baby go to the moon

0 · Reply

ka1954 Jun. 12 at 2:02 PM

$TNFA why do i have the most hated penny stocks

1 · Reply

Hdheheh Jun. 12 at 1:41 PM

$TNFA waiting for random pump

0 · Reply

SCTrader58 Jun. 12 at 5:25 AM

$TNFA give it 3 or 4 weeks to recover from the dump. Maybe mid-July it sets up again after a long consolidation. It wasn't an accident the market maker pulled the liquidity at .34. There wasn't enough volume for a warrant run so they shut it down.

2 · Reply

lost200 Jun. 11 at 5:58 PM

$TNFA @ZackMorris come on bro pump this

0 · Reply